Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
$4.02
-1.2%
$4.37
$3.50
▼
$5.45
$616.23M0.842.94 million shs2.99 million shs
Geron Corporation stock logo
GERN
Geron
$0.87
-4.7%
$1.14
$0.84
▼
$2.01
$560.49M0.6214.19 million shs13.83 million shs
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$1.76
+2.9%
$1.20
$0.56
▼
$2.72
$193.92M1.715.01 million shs7.64 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$194.18
-2.6%
$206.87
$22.28
▼
$280.80
$78.57B1.1612.46 million shs9.64 million shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
-0.58%+1.39%-5.64%-21.57%-4.31%
Geron Corporation stock logo
GERN
Geron
-7.86%-8.15%-26.37%-39.93%-15.46%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
+1.18%+17.12%+69.31%+44.92%-3.93%
Moderna, Inc. stock logo
MRNA
Moderna
+1.29%-13.84%-17.66%+37.40%+724.36%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
$4.02
-1.2%
$4.37
$3.50
▼
$5.45
$616.23M0.842.94 million shs2.99 million shs
Geron Corporation stock logo
GERN
Geron
$0.87
-4.7%
$1.14
$0.84
▼
$2.01
$560.49M0.6214.19 million shs13.83 million shs
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$1.76
+2.9%
$1.20
$0.56
▼
$2.72
$193.92M1.715.01 million shs7.64 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$194.18
-2.6%
$206.87
$22.28
▼
$280.80
$78.57B1.1612.46 million shs9.64 million shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
-0.58%+1.39%-5.64%-21.57%-4.31%
Geron Corporation stock logo
GERN
Geron
-7.86%-8.15%-26.37%-39.93%-15.46%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
+1.18%+17.12%+69.31%+44.92%-3.93%
Moderna, Inc. stock logo
MRNA
Moderna
+1.29%-13.84%-17.66%+37.40%+724.36%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
2.00
HoldN/AN/A
Geron Corporation stock logo
GERN
Geron
2.33
Hold$3.75321.82% Upside
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.50
Moderate Buy$6.33267.15% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.08
Hold$120.25-37.66% Downside

Current Analyst Ratings Breakdown

Latest INO, MRNA, ABUS, and GERN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/17/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetUnderweight$77.00 ➝ $102.00
11/17/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetEqual Weight$95.00 ➝ $200.00
11/12/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Reiterated RatingBuy$5.00
11/11/2026
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
UpgradeHold (C) ➝ Hold (C+)
11/11/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Reiterated RatingSell (E+)
11/11/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Reiterated RatingOverweight$8.00 ➝ $6.00
11/9/2026
Geron Corporation stock logo
GERN
Geron
UpgradeSell (E+) ➝ Sell (D-)
11/9/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingOverweight$230.00 ➝ $305.00
11/9/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetNeutral$137.00 ➝ $195.00
11/6/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Reiterated RatingBuy$3.00 ➝ $8.00
11/2/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Set Price TargetNeutral ➝ Buy$5.00
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
$14.08M44.15N/AN/A$0.56 per share7.24
Geron Corporation stock logo
GERN
Geron
$183.88M3.11N/AN/A$0.35 per share2.54
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$60K3,167.68N/AN/A($0.31) per share-5.56
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B40.15N/AN/A$16.90 per share11.41
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
-$33.50M$1.133.57N/AN/A121.17%129.12%89.26%N/A
Geron Corporation stock logo
GERN
Geron
-$83.50M-$0.08N/A7.41N/A-23.04%-16.29%-6.82%N/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$84.95M-$0.54N/AN/AN/AN/A-28,886.30%-75.67%N/A
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$7.10N/AN/AN/A-110.46%-25.79%-15.85%N/A

Latest INO, MRNA, ABUS, and GERN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/10/2026Q3 2026
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
-$0.0232$0.30+$0.3232$0.30$1.00 million$0.30 million
11/10/2026Q3 2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$0.2067-$0.50-$0.2933-$0.50$2.27 million$0.30 million
11/6/2026Q3 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$1.10$0.38+$1.48$0.38$890.25 million$1.31 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
N/AN/AN/AN/AN/A
Geron Corporation stock logo
GERN
Geron
N/AN/AN/AN/AN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
N/A
1.40
1.40
Geron Corporation stock logo
GERN
Geron
0.53
6.31
4.61
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/A
0.57
0.57
Moderna, Inc. stock logo
MRNA
Moderna
0.52
3.62
3.47

Institutional Ownership

CompanyInstitutional Ownership
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
43.79%
Geron Corporation stock logo
GERN
Geron
73.71%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
26.79%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
19.90%
Geron Corporation stock logo
GERN
Geron
1.71%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
1.70%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
19153.29 million122.79 millionOptionable
Geron Corporation stock logo
GERN
Geron
258644.24 million633.22 millionOptionable
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
112110.18 million108.31 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700404.62 million360.92 millionOptionable

Recent News About These Companies

Best Biotech Stocks To Research - November 20th
Moderna (NASDAQ:MRNA) Stock: Insider Stephen Hoge Sells 39,160 Shares
Bireme Capital Sold Moderna (MRNA) Following Record Rally
Moderna: Can the Vaccine Business Fund Its Next Phase of Growth?
Bireme Capital Sold Moderna (MRNA) Following Record Rally
Moderna (NASDAQ:MRNA) President Sells $8,298,286.15 in Stock
Best Biotech Stocks To Consider - November 18th

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Arbutus Biopharma stock logo

Arbutus Biopharma NASDAQ:ABUS

$4.02 -0.05 (-1.23%)
Closing price 04:00 PM Eastern
Extended Trading
$4.03 +0.01 (+0.12%)
As of 04:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Geron stock logo

Geron NASDAQ:GERN

$0.87 -0.04 (-4.71%)
Closing price 03:59 PM Eastern
Extended Trading
$0.88 +0.01 (+0.92%)
As of 04:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Inovio Pharmaceuticals stock logo

Inovio Pharmaceuticals NASDAQ:INO

$1.76 +0.05 (+2.92%)
Closing price 04:00 PM Eastern
Extended Trading
$1.76 0.00 (0.00%)
As of 04:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Moderna stock logo

Moderna NASDAQ:MRNA

$194.18 -5.15 (-2.58%)
Closing price 03:58 PM Eastern
Extended Trading
$196.65 +2.47 (+1.27%)
As of 04:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.